Compare Revvity Inc (RVTY) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Visa Inc — how do they compare? Revvity Inc trades at $152.05 (market cap $16.98B), while Visa Inc trades at $374 (market cap $704.20B). The key difference: Visa Inc is far larger — about 41.5× Revvity Inc's market cap, and Visa Inc pays the higher dividend (0.71%). Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Visa Inc for 115 Days on average.
| RVTY | V | |
|---|---|---|
Market Cap | $16.98B | $704.20B |
Volume | 1,456,900 | 6,405,857 |
Sector | Health | Financials |
52-Week High | $157.36 | $384.14 |
52-Week Low | $82.26 | $295.52 |
Typical Hold Time | 12 Days | 115 Days |
Enterprise Value | $19.30B | $714.78B |
Dividend Yield | 0.18% | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
Visa (V) trades at $372.10, up 0.39% with strong bullish technical momentum. The company demonstrates robust fundamentals with 2025 revenue of $40B and net income margin of 50.78%. Recent earnings beats and a consensus price target of $422.24 reflect Wall Street optimism. Visa's expansion into AI-powered commerce through Intelligent Commerce Connect positions it for future growth while maintaining exceptional profitability metrics including 61.79% ROE.
Visa presents a compelling investment case with consistent earnings outperformance and dominant market position. Key opportunities include AI integration and stablecoin partnerships, while risks involve regulatory scrutiny and fintech competition. With 85% analyst buy ratings and 13% upside to consensus target, the stock offers growth potential despite premium valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
